Date: 2014-11-14
Type of information: Nomination
Compound: chief scientific officer
Company: Newlink Genetics (USA - IO)
Therapeutic area: Cancer - Oncology - Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On November 14, 2014, NewLink Genetics Corporation announced that Thomas P. Monath, M.D. has been appointed Chief Scientific and Chief Operations Officer of its wholly-owned subsidiary, BioProtection Systems Corporation. Dr. Monath is a world-renowned virologist and vaccinologist with over 25 years of experience as a senior biotechnology industry executive, more than 20 years of experience providing service to the Centers for Disease Control and the United States Army with expertise in viral infections, and almost 400 publications in the field. Dr. Monath has successfully developed and provided clinical trial oversight of multiple vaccines and has extensive experience and success working with the FDA. Dr. Monath\'s main focus will be to provide oversight and direction of the development of the company\'s VSV-EBOV Ebola vaccine candidate licensed from the Public Health Agency of Canada.
Financial terms:
Latest news:
Is general: Yes
